Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.
Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA. Strobel H, et al. Among authors: debatin km. Biomedicines. 2019 Sep 9;7(3):69. doi: 10.3390/biomedicines7030069. Biomedicines. 2019. PMID: 31505812 Free PMC article. Review.
Considering the Experimental use of Temozolomide in Glioblastoma Research.
Herbener VJ, Burster T, Goreth A, Pruss M, von Bandemer H, Baisch T, Fitzel R, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA, Strobel H. Herbener VJ, et al. Among authors: debatin km. Biomedicines. 2020 Jun 4;8(6):151. doi: 10.3390/biomedicines8060151. Biomedicines. 2020. PMID: 32512726 Free PMC article. Review.
Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.
Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM. Westhoff MA, et al. Among authors: debatin km. Mol Cancer Res. 2013 Dec;11(12):1611-23. doi: 10.1158/1541-7786.MCR-13-0435-T. Epub 2013 Oct 21. Mol Cancer Res. 2013. PMID: 24145173
Killing me softly--future challenges in apoptosis research.
Westhoff MA, Brühl O, Nonnenmacher L, Karpel-Massler G, Debatin KM. Westhoff MA, et al. Among authors: debatin km. Int J Mol Sci. 2014 Mar 3;15(3):3746-67. doi: 10.3390/ijms15033746. Int J Mol Sci. 2014. PMID: 24595238 Free PMC article. Review.
RIST: a potent new combination therapy for glioblastoma.
Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM. Nonnenmacher L, et al. Among authors: debatin km. Int J Cancer. 2015 Feb 15;136(4):E173-87. doi: 10.1002/ijc.29138. Epub 2014 Sep 1. Int J Cancer. 2015. PMID: 25123598 Free article.
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, Hlavac M, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME. Karpel-Massler G, et al. Among authors: debatin km. J Neurooncol. 2015 Mar;122(1):21-33. doi: 10.1007/s11060-014-1688-7. Epub 2014 Dec 19. J Neurooncol. 2015. PMID: 25524815
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.
Westhoff MA, Karpel-Massler G, Brühl O, Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L, Debatin KM. Westhoff MA, et al. Among authors: debatin km. Mol Cell Ther. 2014 Oct 27;2:32. doi: 10.1186/2052-8426-2-32. eCollection 2014. Mol Cell Ther. 2014. PMID: 26056598 Free PMC article. Review.
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA, Halatsch ME, Debatin KM. Ströbele S, et al. Among authors: debatin km. PLoS One. 2015 Jun 29;10(6):e0131670. doi: 10.1371/journal.pone.0131670. eCollection 2015. PLoS One. 2015. PMID: 26121251 Free PMC article.
529 results